Funding profile · Drug delivery

Pirouette Pharma

Five Form D filings, two crowdfunding campaigns and one NIH grant line. The filings and the announcements broadly agree. The signatures on them do not stay still.

$13.96MSold across five Form D filings, Jul 2021 to Mar 2026
$12.68MWefunder total from 4,906 investors, as of Sep 22, 2026
$24.9MTotal prior capital raised, company figure via Kingscrowd, Feb 2026
$479KNIH SBIR on record, NIDA R43DA059474

Data as of September 22, 2026. Company-reported figures are labeled. The two totals overlap: the 2025 and 2026 Form D filings are the accredited side of the crowdfunding campaigns.

Rounds at a glance

When Round Amount Investors Source
Jul 2021 Convertible, Rule 506(b) $1,025,000 of $1,250,000 8 · minimum investment $50,000 Form D
Sep 2021 Preferred equity, Rule 506(b) $6,950,000 of $10,570,765 29 Form D
Jun 2022 Convertible, Rule 506(b) $2,550,000 of $15,000,000 2 Form D
May 2024 to Mar 2025 Wefunder round, SAFE, $55M cap $7,953,327 4,000 plus Platform data
Apr 2025 Preferred equity, Rule 506(c) $2,350,000 of $3,500,000 1 · pooled via Wefunder Form D
Feb to Mar 2026 Wefunder round, SAFE, $95M cap $4,979,659 Closed Mar 27, 2026 Platform data
Mar 2026 Preferred equity, Rule 506(c) $1,080,537 of $6,000,000 1 · pooled via Wefunder Form D
2023 to 2024 NIH NIDA SBIR Phase I and supplements $479,080 NIDA NIH RePORTER

What the filings show

Pirouette Pharma Inc. · Form D · filed Mar 18, 2026

First sale
Mar 10, 2026
Offered
$6,000,000
Sold
$1,080,537 · $4,919,463 remaining
Investors
1 · Wefunder Portal LLC compensated
Exemption
Rule 506(c)
Related persons
Cullinane, Kane, Kapas as officers and promoters; Nemmers and Motamedy as directors
Filing
SEC EDGAR, CIK 0001870611

Pirouette Pharma Inc. · Form D · filed Apr 1, 2025

First sale
Mar 28, 2025
Offered
$3,500,000
Sold
$2,350,000 · $1,150,000 remaining
Investors
1 · Wefunder Portal LLC compensated
Exemption
Rule 506(c)
Related persons
Same five. First filing under the Pirouette Pharma name
Filing
SEC EDGAR, CIK 0001870611

Pirouette Medical Inc. · Form D · filed Jun 15, 2022

First sale
May 31, 2022
Offered
$15,000,000 convertible
Sold
$2,550,000 · $12,450,000 remaining
Investors
2 · average $1,275,000
Exemption
Rule 506(b)
Related persons
Cullinane; Nemmers; Motamedy. Address now Portsmouth, NH; incorporated 2017
Filing
SEC EDGAR, CIK 0001870611

Pirouette Medical Inc. · Form D · filed Sep 2, 2021

First sale
Aug 19, 2021
Offered
$10,570,765 equity
Sold
$6,950,000 · $3,620,765 remaining
Investors
29 · average about $239,655
Exemption
Rule 506(b)
Related persons
Cullinane; Nemmers; Arunas Chesonis, all as officer, director and promoter
Filing
SEC EDGAR, CIK 0001870611

Pirouette Medical Inc. · Form D · filed Jul 6, 2021

First sale
Jun 21, 2021
Offered
$1,250,000 convertible · minimum investment $50,000
Sold
$1,025,000 · $225,000 remaining
Investors
8 · average about $128,125
Exemption
Rule 506(b)
Related persons
Cullinane; Kapas; Kane, all as officer, director and promoter. Address Arlington, MA
Filing
SEC EDGAR, CIK 0001870611

Reading the filings

  1. Two filings report one investor each, which is not what it sounds like.The April 2025 and March 2026 Form Ds each list a single investor and name Wefunder Portal LLC as receiving sales compensation. That is the Rule 506(c) accredited side of a crowdfunding campaign, where the platform pools accredited money into one entity. One investor on the filing stands for an unknown number behind it.
  2. The early money came in institutional sizes.September 2021: $6,950,000 from 29 investors, about $239,655 each. July 2021 before it: $1,025,000 from 8 investors, about $128,125 each, against a stated $50,000 minimum.
  3. The related-persons roster keeps changing.Arunas Chesonis, managing partner of Safar Partners, is an executive officer, director and promoter on the September 2021 filing and on no other. Kane and Kapas are on the July 2021 filing, vanish from the next two, and return in 2025 and 2026. Cullinane is on all five.
  4. Three years without a Form D is not three years without money.Nothing was filed between June 2022 and April 2025, and the May 2024 announcement of a round past $5 million sits inside that gap. Crowdfunding runs on Form C; a Section 4(a)(2) placement needs neither.
  5. The large offerings stayed mostly unsold.June 2022 offered $15,000,000 and sold $2,550,000. March 2026 offered $6,000,000 and sold $1,080,537. No amendment has been filed on either.
  6. The grant figure in the deal data is low.Kingscrowd lists $352K in grants. NIH RePORTER records $326,500 in FY2023 plus FY2024 supplements of $55,000 and $97,580 under NIDA award R43DA059474, or $479,080.

Commercial signals

Signal Detail Source type
Regulatory No 510(k), PMA, device registration and listing, approved drug application or NDC under Pirouette Medical or Pirouette Pharma in openFDA queries run Sep 22, 2026. Public record
FDA process Pre-submission meetings, a completed Type C meeting and an IND referenced in January 2026. First approval targeted for 2027. Company-stated
Revenue and burn Revenue $0 in FY2024. Monthly burn $517,200, runway 3.1 months, January 2026. Company data via Kingscrowd
Manufacturing Portsmouth facility of 10,000 square feet with an ISO Class 8 clean room, announced Oct 10, 2025. Company-stated
Partnerships Four pharmaceutical partnerships and licensing potential above $800 million claimed. No counterparty named. Company-stated
Intellectual property Five granted US patents on record, 2019 to 2024. Company claims 23 granted globally to 2045. Public record and claim
Platform standing The Wefunder page calls it the “#1 most raised campaign in Wefunder history”. Kingscrowd put the 2026 round at 139.6% of its target maximum. Independent

What to watch

  • A Form D or Form C after March 2026. The reported January 2026 runway ran to roughly April 2026.
  • Amended Form Ds on the June 2022 and March 2026 offerings, which still show large unsold balances.
  • A priced round. Both community campaigns sold SAFEs, and the cap moved from $55 million to $95 million in twelve months with none disclosed in between.
  • A named licensing counterparty, and any FDA record at all under either name.

The Pirouette Pharma story on Healthcare DiscoveryHealthcare Discovery

Related companies

  • Macromoltek: Shared investor: Company-Stated Partners. An Austin software company that has designed antibodies inside a computer since 2011, paid for by federal grants and customer fees rather than venture rounds
  • Abalone Bio: Shared investor: Company-Stated Partners. An East Bay biotech that screens antibodies for what they do to a receptor, not how tightly they stick to it
  • TAXA Biotechnologies: Shared investor: Company-Stated Partners. The company behind the first synthetic biology crowdfunding campaign
  • CB Therapeutics: Shared investor: Company-Stated Partners. A Carlsbad company that brews cannabinoids, psilocybin and other plant and fungal molecules in engineered yeast

Sources

  1. Public recordFive Form D filings, Pirouette Medical Inc. and Pirouette Pharma Inc., CIK 0001870611SEC · Jul 2021 to Mar 2026
  2. Public recordNIH RePORTER, R43DA059474 and supplementsNIH NIDA · FY2023 to FY2024
  3. Public recordopenFDA and ClinicalTrials.gov queries for PirouetteFDA and NIH · Sep 22, 2026
  4. Public recordUS patents 10265471, 10441714, 10722653, 11324882, 12011569USPTO via Justia Patents
  5. IndependentPirouette Pharma on Wefunder 2026, deal terms and funding historyKingscrowd · Feb 9, 2026
  6. IndependentFebruary 2026: A More Selective Month for Investment CrowdfundingKingscrowd · Mar 10, 2026
  7. IndependentThe $7.2 Million WeekSuperpowers for Good · Apr 5, 2026
  8. IndependentPirouette: Over $5 Million Raised Via WeFunderPulse 2.0 · May 16, 2024
  9. CompanySafar Partners Leads Pirouette’s Investment Round with $5M+ RaisedBusiness Wire · May 7, 2024
  10. CompanyPirouette Pharma investor and news pages; Wefunder campaign pageAccessed Sep 22, 2026

Compiled from SEC, NIH, USPTO and FDA public records and published reports as of September 22, 2026. Form D notices report offerings under Regulation D; amounts reflect the filing date and may not capture later sales. Regulation Crowdfunding totals are reported by the platform and by Kingscrowd, not by the SEC on Form D. Healthcare Venture Capital Fund holds no position in Pirouette Pharma. This page is not an offer to sell or a recommendation to buy any security.